Key facts
- Notable investors include LongGame.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Totality Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Totality Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Totality Biosciences
Developer of bio-derived nutritional and bioprotective compounds designed for human health applications. The company's platform uses genetically engineered plant systems to biosynthesize a broad and structurally diverse range of complex oligosaccharides naturally found in human milk, with capabilities for full-spectrum molecular coverage, scalable agricultural production, substantially increased output capacity compared to microbial methods, and lower projected production costs, enabling nutrition, infant health, and biomedical research markets to access larger volumes and wider varieties of biologically relevant compounds for clinical, nutritional, and therapeutic development.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2025
- Employees
- 2
- Website
- totalitybiosciences.com/
- Ownership
- Privately Held (backing)
Totality Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Totality Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Totality Biosciences in its N-PORT filings yet. We sweep new filings monthly.